UKWURU THERAPEUTICS
Ukwuru Therapeutics is an Ukwuru science research journal. It spans all therapeutics research conducted by Ukwuru Science Study Group (USSG), Independent Researchers (IR), and Companies.
Authors
Ukwuru, E.I. and Akpevba, E.
Key Findings
There was no statistically significant relationship between Doravirine and efficacy; however, Doravirine was statistically associated with safety (p<.00001).
Key Findings
SP was better for preventing placental parasitaemia (Z = 6.70; p < 0.00001), maternal anaemia (p < 0.00001), and adverse outcomes (p < 0.00001), but not low-birth-weight (p=0.08).
Authors
Ukwuru, E.I. and Akpevba, E.
Key Findings
Pharmacogenetic testing is superior to non-pharmacogenetic testing before Warfarin therapy in the prevention of adverse events (p<.00001) but not for achieving TTR and INR.
Authors
Ukwuru, E.I. and Okeke, L.O.
Key Findings
FLT3 dual therapy is significantly more effective than the monotherapy (p<.00001). Both FLT3 dual therapy and FLT3 monotherapy are equally safe (p<.00001).
